I don’t know about that, but XDx just raised filed for a $87 million in an IPO. So far, expression based diagnostics have had a tough time for various reasons, including lack of patient education, cost, and insurance barriers. The IPO and other recent events seem to suggest that maybe, just maybe, the tide is turning. I also think that the issue of home brew vs. FDA approval needs to be resolved sooner rather than later.
David Hamilton, as usual, has excellent coverage of the story.
Will write more when I have some time. Too busy right now.
Please read the standard disclaimer. My company develops software for gene expression analysis, including software used by some companies in the diagnostic space.
Technorati Tags: XDx, Gene Expression, Diagnostics
3 Comments
Actually, XDx has only filed to raise the $87 million. It’ll be a while before we know whether they can pull it off or not.
David
Thanks for clarifying. Doing things in such a hurry these days, missed that rather important detail
David
Thanks for clarifying. Doing things in such a hurry these days, missed that rather important detail